B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

BACKGROUND: B cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but an optimal RTX treatment schedule is unknown and the time to B cell repopulati...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Arthritis Res Ther
Autori principali: Thiel, Jens, Rizzi, Marta, Engesser, Marie, Dufner, Ann-Kathrin, Troilo, Arianna, Lorenzetti, Raquel, Voll, Reinhard E., Venhoff, Nils
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437549/
https://ncbi.nlm.nih.gov/pubmed/28521808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1306-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi